Please wait...

Learn

Finding accredited CPD

Australasian Diabetes Congress 2026 Conference Review

Description

This is a summary of the Australasian Diabetes Congress 2026 Conference Review which was recently held in Melbourne.

Commentary provided by Dr Natalie Nanayakkara.

In this edition we feature:

OASIS 4: semaglutide 25mg in overweight/obesity
REMODEL: kidney benefits with semaglutide in type 2 diabetes
REMODEL: kidney benefits with semaglutide by SGLT2i use
Liver fibrosis in type 2 diabetes
TZP-T1D: tirzepatide in type 1 diabetes with overweight/obesity
SYNCHRONIZE™-1: survodutide in obesity without diabetes
SYNCHRONIZE™-MASLD: survodutide in obesity with MASLD
Time in tight range & incident diabetic retinopathy in type 2 diabetes
Dapagliflozin with continuous ketone monitoring in type 1 diabetes
Lifestyle factors & type 2 diabetes risk after gestational diabetes

Details

To access this publication please click ‘Enrol Now’ and you’ll be directed to the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide.

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.

Provided by

CPD Activity Details

Topic

Endocrine System Diseases, Nutritional and Metabolic Diseases

CAPE Aspects

Effective Year

Educational Activities (EA) - 0.30

Reviewing Performance (RP) - 0.0

Measuring Outcomes (MO) - 0.0

You have to log in to see the content of this module.